Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@article{Tarhini2010PhaseIS,
  title={Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.},
  author={Ahmad A Tarhini and Athanasios A Kotsakis and W. E. Gooding and Yongli Shuai and Daniel P Petro and David P Friedland and Chandra Prakash Belani and Sanja Dacic and Athanassios Argiris},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 23},
  pages={5900-7}
}
PURPOSE Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed SCLC. EXPERIMENTAL DESIGN Patients were treated with everolimus 10 mg orally daily until disease progression. The primary endpoint was disease control rate (DCR) at 6 weeks. PI3K/Akt signaling pathway biomarkers were evaluated on baseline tumor tissue. RESULTS A total of 40 patients were treated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer.

International journal of clinical and experimental pathology • 2015
View 12 Excerpts
Highly Influenced

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…